OS Therapies (OSTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.32, -6.38% vs the prior close of $1.41.
- Volume 527.87K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
OSTX slides 6.4% to $1.32, a 6-month low. Closed at $1.32, -6.38% vs the prior close of $1.41. Day range $1.30–$1.43, opened at $1.42.
OSTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — OSTX slides 6.4% to $1.32, a 6-month low
- Closed at $1.32, -6.38% vs the prior close of $1.41. Day range $1.30–$1.43, opened at $1.42.
- Volume was 527.87K shares, 0.8x its 50-day average of 658.40K.
- Price is -19.2% vs its 50-day average ($1.63) and -16.2% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 15% of that range, 41.3% below the 52-week high.
Oct 15, 2026 — OSTX rises 1.4% to $1.41
- Closed at $1.41, +1.44% vs the prior close of $1.39. Day range $1.38–$1.44, opened at $1.38.
- Volume was 375.20K shares, 0.6x its 50-day average of 655.77K — lighter than usual.
- Price is -14.1% vs its 50-day average ($1.64) and -10.5% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 24% of that range, 37.3% below the 52-week high.
Oct 14, 2026 — OSTX slides 4.1% to $1.39, a 3-month low, 4 down days in a row
- Closed at $1.39, -4.14% vs the prior close of $1.45. Day range $1.38–$1.48, opened at $1.45.
- Volume was 495.00K shares, 0.8x its 50-day average of 652.85K.
- Price is -15.5% vs its 50-day average ($1.64) and -11.8% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 22% of that range, 38.2% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — OSTX slides 7.1% to $1.45, a 1-month low, 3 down days in a row
- Closed at $1.45, -7.05% vs the prior close of $1.56. Day range $1.45–$1.58, opened at $1.57.
- Volume was 810.60K shares, 1.3x its 50-day average of 640.92K.
- Price is -12.1% vs its 50-day average ($1.65) and -8.0% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 27% of that range, 35.6% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — OSTX slides 3.7% to $1.56
- Closed at $1.56, -3.70% vs the prior close of $1.62. Day range $1.56–$1.62, opened at $1.61.
- Volume was 242.10K shares, 0.4x its 50-day average of 642.74K — lighter than usual.
- Price is -5.5% vs its 50-day average ($1.65) and -1.1% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 37% of that range, 30.7% below the 52-week high.
Oct 9, 2026 — OSTX ends flat (+0.0%) to $1.62
- Closed at $1.62, +0.00% vs the prior close of $1.62. Day range $1.59–$1.66, opened at $1.62.
- Volume was 418.30K shares, 0.7x its 50-day average of 639.14K.
- Price is -1.9% vs its 50-day average ($1.65) and +2.7% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 43% of that range, 28.0% below the 52-week high.
Oct 8, 2026 — OSTX jumps 4.5% to $1.62
- Closed at $1.62, +4.52% vs the prior close of $1.55. Day range $1.54–$1.68, opened at $1.55.
- Volume was 662.90K shares, 1.1x its 50-day average of 630.43K.
- Price is -1.8% vs its 50-day average ($1.65) and +2.7% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 43% of that range, 28.0% below the 52-week high.
Oct 7, 2026 — OSTX jumps 4.0% to $1.55
- Closed at $1.55, +4.03% vs the prior close of $1.49. Day range $1.46–$1.57, opened at $1.50.
- Volume was 586.70K shares, 0.9x its 50-day average of 624.50K.
- Price is -5.9% vs its 50-day average ($1.65) and -1.7% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 36% of that range, 31.1% below the 52-week high.
Oct 6, 2026 — OSTX slides 6.9% to $1.49, a 1-month low on 11.8x normal volume
- Closed at $1.49, -6.88% vs the prior close of $1.60. Day range $1.47–$1.74, opened at $1.71.
- Volume was 6.01M shares, 11.8x its 50-day average of 508.63K — unusually heavy trading.
- Price is -9.5% vs its 50-day average ($1.65) and -5.5% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 31% of that range, 33.8% below the 52-week high.
Oct 5, 2026 — OSTX dips 1.2% to $1.60
- Closed at $1.60, -1.23% vs the prior close of $1.62. Day range $1.57–$1.63, opened at $1.61.
- Volume was 416.20K shares, 0.8x its 50-day average of 505.12K.
- Price is -2.8% vs its 50-day average ($1.65) and +1.4% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 41% of that range, 28.9% below the 52-week high.
- SEC filings that day: 8-K.
Oct 2, 2026 — OSTX rises 0.6% to $1.62
- Closed at $1.62, +0.62% vs the prior close of $1.61. Day range $1.62–$1.66, opened at $1.62.
- Volume was 232.90K shares, 0.5x its 50-day average of 505.30K — lighter than usual.
- Price is -1.5% vs its 50-day average ($1.64) and +2.7% vs its 200-day average ($1.58).
- 52-week range $1.15–$2.25; today's close sits at 43% of that range, 28.0% below the 52-week high.
OSTX latest news & SEC filings
Every SEC filing by or about OSTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Oct 5, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Oct 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 8.01 — Reported other events the company considers important.
Sep 21, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Sep 10, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 10, 2026 · Form 424B7 — Prospectus supplement for a resale by holders
Prospectus supplement for a resale by holders
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Aug 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 21, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 14, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$8.63M (prior year -$4.54M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.20 (prior year -$0.19) (loss widened vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
Aug 6, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Jul 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.02 — Ended a material agreement.
Things to know before you trade OSTX
- Last results release: Aug 19, 2025 (8-K Item 2.02). Previous ones: May 16, 2025, Mar 31, 2025, Nov 15, 2024. Based on that rhythm, the next report is likely around Nov 18, 2025 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.75% (largest 7.1%).
- Liquidity: about 744.27K shares (≈$982.43K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.32 vs a range of $1.15–$2.25 (15% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 5, 2026; 8-K Sep 10, 2026; 8-K Sep 9, 2026.
- Share count: 46.13M shares outstanding (Aug 12, 2026), +44.6% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Pharmaceutical Preparations.
OSTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.42 | 1.43 | 1.30 | 1.32 | 527.87K |
| Oct 15, 2026 | 1.38 | 1.44 | 1.38 | 1.41 | 375.20K |
| Oct 14, 2026 | 1.45 | 1.48 | 1.38 | 1.39 | 495.00K |
| Oct 13, 2026 | 1.57 | 1.58 | 1.45 | 1.45 | 810.60K |
| Oct 12, 2026 | 1.61 | 1.62 | 1.56 | 1.56 | 242.10K |
| Oct 9, 2026 | 1.62 | 1.66 | 1.59 | 1.62 | 418.30K |
| Oct 8, 2026 | 1.55 | 1.68 | 1.54 | 1.62 | 662.90K |
| Oct 7, 2026 | 1.50 | 1.57 | 1.46 | 1.55 | 586.70K |
| Oct 6, 2026 | 1.71 | 1.74 | 1.47 | 1.49 | 6.01M |
| Oct 5, 2026 | 1.61 | 1.63 | 1.57 | 1.60 | 416.20K |
| Oct 2, 2026 | 1.62 | 1.66 | 1.62 | 1.62 | 232.90K |
| Oct 1, 2026 | 1.62 | 1.65 | 1.56 | 1.61 | 329.50K |
| Sep 30, 2026 | 1.60 | 1.67 | 1.59 | 1.60 | 475.10K |
| Sep 29, 2026 | 1.64 | 1.66 | 1.60 | 1.61 | 549.50K |
| Sep 28, 2026 | 1.66 | 1.68 | 1.61 | 1.65 | 353.10K |
| Sep 25, 2026 | 1.67 | 1.68 | 1.64 | 1.66 | 170.30K |
| Sep 24, 2026 | 1.66 | 1.67 | 1.62 | 1.66 | 344.80K |
| Sep 23, 2026 | 1.76 | 1.77 | 1.64 | 1.65 | 653.40K |
| Sep 22, 2026 | 1.76 | 1.84 | 1.74 | 1.77 | 599.70K |
| Sep 21, 2026 | 1.81 | 1.82 | 1.74 | 1.74 | 636.40K |
About OS Therapies
OS Therapies (OSTX) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in ROCKVILLE, MD. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1795091.
OSTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| John Ciccio | Director | Feb 13, 2026 |
| Craig Eagle | Director | Jul 23, 2026 |
| Karim Galzahr | Director | Feb 13, 2026 |
| Olivier Roger Jarry | Director | Feb 13, 2026 |
| Avril Suzette Mckean-Dieser | Director | Feb 13, 2026 |
| Paul A. Romness | President and CEO | May 15, 2026 |
| Theodore F. Search | Director | Feb 13, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christopher P. Acevedo | Chief Financial Officer | Feb 13, 2026 |
| Robert Petit | See Remarks | Feb 13, 2026 |
| Paul A. Romness | President and CEO | May 15, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
OSTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-28.75M | -0.98 | $-14.24M |
| Dec 31, 2024 | — | $-8.88M | -1.28 | $-7.28M |
| Dec 31, 2023 | — | $-7.79M | -1.46 | $-3.01M |
Latest balance sheet: total assets $9.90M, total liabilities $20.74M, cash $— (as of Jun 30, 2026).
OSTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 19, 2025 | 8-K Item 2.02 (results) | $2.15 |
| May 16, 2025 | 8-K Item 2.02 (results) | $1.64 |
| Mar 31, 2025 | 8-K Item 2.02 (results) | $1.54 |
| Nov 15, 2024 | 8-K Item 2.02 (results) | $2.20 |
| Aug 15, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on OSTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.